Actively Recruiting
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
Led by Zhongnan Hospital · Updated on 2025-04-20
150
Participants Needed
1
Research Sites
105 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study is being done to evaluate the potential benefits of using electroacupuncture to reduce the severity of chemotherapy-induced peripheral neuropathy for patients with peripheral neuropathy after chemotherapy.
CONDITIONS
Official Title
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years of age or older, of any nationality.
- Diagnosed with malignant tumor.
- Chemotherapy-induced peripheral neuropathy symptoms graded 2 to 3 on NCI-CTCAE v5.0.
- Predicted life expectancy of at least 3 months.
- Intact skin without any breaches or purulent discharge.
- Able to comply with the study protocol and provide written informed consent.
You will not qualify if you...
- History of peripheral neuropathy before chemotherapy, including causes like alcoholism, vitamin B deficiency, diabetes, HIV, congenital or toxic neuropathy.
- Skin damage, pus, or scars at the acupuncture stimulation area.
- Pregnancy or breastfeeding.
- Significant mental health conditions.
- Receiving other acupuncture treatments during the trial.
- Not meeting inclusion criteria.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongnan hospital of Wuhan University
Wuhan, Hubei, China
Actively Recruiting
Research Team
H
Haijun Yu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here